Background: Although genetic mutations in additional sex-combs-like 1 (ASXL1) are
prevalent in acute myeloid leukemia (AML), their exact impact on the AML prognosis …

A large-scale genomic analysis of patients with ASXL1-mutated myeloid disease has not
been performed to date. We reviewed comprehensive genomic profiling results from 6043 …

Objective The objective of the study was to determine the prognosis and risk factors for
additional sex combs like 1 (ASXL1) mutations in patients with acute myeloid leukemia …

Objectives Mutations in ASXL1 are being investigated for prognostic value in AML, but the
relationship between these mutations and prognosis for patients with AML remains unclear …

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) generally confers
poor prognosis; however, the clinical outcome remains heterogeneous. We sought to further …

Background/Aim: Mutations in the ASXL transcriptional regulator 1 (ASXL1) and splicing
factor 3b subunit 1 (SF3B1) genes are commonly observed in myeloid neoplasms and are …

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) includes
heterogeneous conditions such as previous history and specific cytogenetic and …

Myeloid malignancies exhibit considerable heterogeneity with overlapping clinical and
genetic features among different subtypes. Current classification schemes, predominantly …

Motivation: Somatic mutations can have critical prognostic and therapeutic implications for
cancer patients. Although targeted methods are often used to assay specific cancer driver …

Background ASXL1 mutation is an independent prognostic factor in adult acute myeloid
leukemia (AML), but its effect on the prognosis of pediatric AML is poorly understood. Aims …